Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ziopharm Oncology has received positive opinion for the orphan drug status of Darinaparsin (Zinapar or ZIO-101) from the Committee of Orphan Medicinal within the European Medicines Agency (EMA) to treat peripheral T-cell lymphoma (PTCL).
Subscribe to our email newsletter
A positive opinion by the COMP immediately precedes official designation of darinaparsin as an orphan drug by the European Commission (EC).
Ziopharm expects to commence a registration-directed study of Darinaparsin in patients with PTCL by the end of 2011.
Ziopharm CEO and chief medical officer Jonathan Lewis said orphan designation recognizes the acute need for new therapies for unmet medical needs, in this case addressing PTCL.